ACHE and Alzheimer disease: Direct PET measurements of the maximum in vivo cortical AChE inhibition that can be tolerated in AD patients undergoing donepezil treatment is estimated at ~19% [82], ~27% [83], ~35% [84], and from 28% to 39%, depending on the cortical area [85].